Everything below concerns freeze-thaw cycling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The study Radiological Evaluation of Breasts Reconstructed with Lipo-modeling (2005) indicates that the therapeutic efficacy of fat-graft breast reconstruction in the treatment of radiation therapy damage to the chest, the incidental reduction of capsular contracture, and the improved coverage of the breast implants. In fat-graft breast augmentation procedures, there is the risk that the adipocyte tissue can become necrotic, undergo metastatic calcification, develop cysts, and agglomerate into palpable lumps. Although the cause of metastatic calcification is unknown, the post-procedure biological changes occurred to the fat-graft tissue resemble the tissue changes usual to breast surgery procedures, such as reduction mammoplasty. The pre-procedure mammograms were negative for the presence of the malignant neoplasms of breast cancer. In the 17-patient cohort, two women developed breast cancer after the breast augmentation: one woman at 12 months and the second woman at 92 months. Further, the study Cell-assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells (2007), in a 40-woman cohort, the inclusion of adipose stem cells in the grafts of adipocyte fat increased the rate of the corrective success of the autologous fat-grafting procedure.
== Further reading == "Becker Muscular Dystrophy (for Parents)." Edited by Mena T. Scavina, KidsHealth, The Nemours Foundation, Mar. 2018, kidshealth.org/en/parents/becker-md.html. Gaudio, Daniela del; Yang, Yaping; Boggs, Barbara A.; Schmitt, Eric S.; Lee, Jennifer A.; Sahoo, Trilochan; Pham, Hoang T.; Wiszniewska, Joanna; Craig Chinault, A.; Beaudet, Arthur L.; Eng, Christine M. (September 2008). "Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridization". Human Mutation. 29 (9): 1100–1107. doi:10.1002/humu.20841. PMID 18752307. S2CID 21437006. Li, Xihua; Zhao, Lei; Zhou, Shuizhen; Hu, Chaoping; Shi, Yiyun; Shi, Wei; Li, Hui; Liu, Fang; Wu, Bingbing; Wang, Yi (2015). "A comprehensive database of Duchenne and Becker muscular dystrophy patients (0–18 years old) in East China". Orphanet Journal of Rare Diseases. 10 (1): 5. doi:10.1186/s13023-014-0220-7. PMC 4323212. PMID 25612904.
A day after his father's death, the National Assembly received clear instructions to dismiss Natchaba and elect Gnassingbé in his place, which would legalize his succession, which took place on 6 February 2005. Gnassingbé's election was unanimously approved by the deputies (98% of them were members of the ruling party) who were present in the National Assembly at the time; the opposition was not represented in the National Assembly due to its boycott of the 2002 parliamentary election. The members of Gnassingbé's then-party, the Rally of the Togolese People (RPT), did not want to challenge the army's choice. The parliament also eliminated a constitutional requirement that elections be held within 60 days of the president's death, enabling the younger Gnassingbé to rule until the expiration of his father's term in 2008. Under pressure from others in the region, and particularly Nigeria, later that month 2005, Gnassingbé announced that new elections would be held within 60 days, but said that he would remain in office in the meantime. However, on 21 February, the National Assembly reversed some of the constitutional changes that it had made so as to allow Gnassingbé to assume power, although it did not instruct him to resign. This was construed as a way of pressuring him to stand down with dignity. To change the constitution during a period of transition was itself an unconstitutional act, but this did not deter Gnassingbé's allies.
Large batches of quantum dots may be synthesized via colloidal synthesis. Due to this scalability and the convenience of benchtop conditions, colloidal synthetic methods are promising for commercial applications.
Sources: en.wikipedia.org
Resistin can increase levels of circulating low-density lipoprotein (LDL) and accelerates LDL accumulation in arteries, increasing risk of heart disease has an adverse impact on the efficacy of statins, the primary drug used to reduce cholesterol in fighting of cardiovascular disease. In the liver, resistin increases LDL production and degrades LDL receptors, impairing the ability to process LDL.
The original synthesis as patented in 1964 by Paul Janssen involves the synthesis of benzylfentanyl from N-benzyl-4-piperodone. The resulting benzylfentanyl is used as feedstock to norfentanyl. It is norfentanyl that forms fentanyl upon reaction with a phenethyl halide.
Site-directed mutagenesis of O-GlcNAc-modified serine or threonine residues to alanine may be used to evaluate the function of O-GlcNAc at specific residues. As alanine's side chain is a methyl group and is thus not able to act as an O-GlcNAc site, this mutation effectively permanently removes O-GlcNAc at a specific residue. While serine/threonine phosphorylation may be modeled by mutagenesis to aspartate or glutamate, which have negatively charged carboxylate side chains, none of the 20 canonical amino acids sufficiently recapitulate the properties of O-GlcNAc. Mutagenesis to tryptophan has been used to mimic the steric bulk of O-GlcNAc, though tryptophan is much more hydrophobic than O-GlcNAc. Mutagenesis may also perturb other post-translational modifications, e.g., if a serine is alternatively phosphorylated or O-GlcNAcylated, alanine mutagenesis permanently eliminates the possibilities of both phosphorylation and O-GlcNAcylation.
== Formulation == Aulus Cornelius Celsus details one version of the antidote in De Medicina (ca. AD 30). A recent translation is as follows: "But the most famous antidote is that of Mithridates, which that king is said to have taken daily and by it to have rendered his body safe against danger from poison". It contained:
== Adverse effects == The most common side effects of pivekimab sunirine include swelling (edema), tiredness (fatigue), muscle and joint pain (musculoskeletal pain), bleeding (hemorrhage), infusion-related reactions, nausea, diarrhea, changes in kidney function tests (increased creatinine), low albumin levels, and changes in liver function tests (transaminases increased). The US prescribing information includes a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease, and warnings and precautions for infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity. Pivekimab sunirine may cause a severe form of liver damage (hepatotoxicity) called veno-occlusive disease (blockage of small blood vessels that makes it hard for blood to leave the liver, leading to backup and swelling), including severe or fatal hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome). Pivekimab sunirine may cause a serious side effect called infusion-related reaction, which may be life-threatening or lead to death if not treated. Pivekimab sunirine contains sulfite and may cause severe, life-threatening allergic reactions in some people. Pivekimab sunirine may cause severe fluid retention and harm to an unborn baby.
Sources: en.wikipedia.org
(1.2) Keey et al. (2000) use a different definition of the fibre saturation point (equilibrium moisture content of wood in an environment of 99% relative humidity). Many properties of wood show considerable change as the wood is dried below the fibre saturation point, including:
=== Capillary electrophoresis-mass spectrometry (CE-MS) === Capillary electrophoresis-mass spectrometry was enabled by an ESI interface that was developed and patented by Richard D. Smith and coworkers at Pacific Northwest National Laboratory, and shown to have broad utility for the analysis of very small biological and chemical compound mixtures, and even extending to a single biological cell.
=== Science and academia === Andy Miah, professor of science communication and future media at the University of Salford, called TEG a "provocation", saying that "... the significant risk of athletes excessively enhancing and risking significant health complications is unaddressed by their materials. There is no mention of medical oversight in the competition on the website, from what I can see." Fraser said that "Each athlete must be under clinical supervision." According to D'Souza, "We will focus on athlete safety by mandating athletes have pre-competition full-system clinical screenings including blood tests and EKGs." Science writer Ronald Bailey said, "Let fans decide which play they prefer." Grigory Rodchenkov, former head of the Moscow Anti-Doping Laboratory, said it was a "danger to health, to sport." Academic John William Devine said, "In a sporting world in which inequality of opportunity is already rampant, the removal of the doping ban would only deepen an existing moral failing." According to John Hoberman, author of several books on sports and doping, D'Souza's idea that drugs would lead to better performance is "very simplistic", and D'Souza is "very shallow on the scientific end". Anti-doping expert Michael Ashenden expressed support for the games in 2024, "provided their athletes do nothing illegal". Science philosopher Byron Hyde said that the large financial incentives offered by TEG risk coercing struggling athletes into participating, undermining their autonomy.
== Clinical comparisons of effectiveness == A 2006 review article in the journal "Lasers in Medical Science" compared intense pulsed light (IPL) and both alexandrite and diode lasers. The review found no statistical difference in effectiveness, but a higher incidence of side effects with diode laser-based treatment. Hair reduction after 6 months was reported as 68.75% for alexandrite lasers, 71.71% for diode lasers, and 66.96% for IPL. Side effects were reported as 9.5% for alexandrite lasers, 28.9% for diode lasers, and 15.3% for IPL. All side effects were found to be temporary and even pigmentation changes returned to normal within 6 months. A 2006 meta-analysis of randomized controlled trials found that alexandrite and diode lasers caused 50% hair reduction for up to 6 months, while there was no evidence of hair reduction from intense pulsed light, neodymium-YAG or ruby lasers.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.